The Asia Pacific Diabetic Retinopathy Market would witness market growth of 11.9% CAGR during the forecast period (2021-2027).
The retina can eventually separate from the back of the eye due to scar tissue formed by the development of new blood vessels. If the new blood vessels obstruct the usual flow of fluid out of the eye, the tension in the eyeball might build up. Glaucoma is caused by a buildup of fluid on the optic nerve, the nerve that transmits images from the eye to the brain.
The more advanced form of the illness is proliferative diabetic retinopathy (PDR). Circulation difficulties are depriving the retina of oxygen at this point. As a result, new and fragile blood vessels in the retina and the vitreous, the gel-like substance that fills the back of the eye, may begin to form. Blood may leak from the developing blood vessels into the vitreous, blurring vision. PDR can also cause retinal detachment as a result of scar tissue production, as well as the occurrence of glaucoma. Progressive vision loss is one of the symptoms, especially in those who are not appropriately monitored or treated. According to data published by Columbia University, the length of diabetes, which increases the incidence of retinopathy by 65 percent, is one of the key risk factors for PDR.
The regional diabetic retinopathy market is increasing because of the rising number of patients with diabetes in Asia-Pacific. In addition, emerging economies in the Asia-Pacific area, such as Japan and China, would develop significantly due to the increasing disposable income of the regional population, a substantial aging population, increased investment for research and development activities for diabetes, and diagnostic innovation. Due to high medical expenses, the Chinese market is growing at a healthy speed. Although Japan is one of the largest markets in the Asia-Pacific region. In addition, the rising adoption of Laser therapy is anticipated to accelerate the demand for diabetic retinopathy treatment.
Due to a huge patient pool along with the advent of technologies and innovation in diagnostic approaches and government health insurance regulations, the diabetic retinopathy market in the Asia Pacific area is booming. According to a report published in the Journal of Diabetology in 2018, over 80 million people in the Asia Pacific area were suffering from diabetes in 2017, with the number anticipated to rise to 151 million by 2045.
The China market dominated the Asia Pacific Diabetic Retinopathy Market by Country in 2020, and would continue to be a dominant market till 2027; thereby, achieving a market value of $583.1 Million by 2027. The Japan market is poised to grow at a CAGR of 11.3% during (2021 - 2027). Additionally, The India market would exhibit a CAGR of 12.7% during (2021 - 2027).
Based on Type, the market is segmented into Proliferative and Diabetic Macular Edema (DME). Based on Treatment Type, the market is segmented into Anti VEGF Drug, Steroid Implants, Laser Surgeries, and Vitrectomy. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
Free Valuable Insights: The Worldwide Diabetic Retinopathy Market is Projected to reach USD 7.7 Billion by 2027, at a CAGR of 11.3%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Allergan PLC (Abbvie, Inc.), Bayer AG, Alimera Sciences, Inc., Novartis AG, Pfizer, Inc., F-Hoffmann-La Roche Ltd., Ampio Pharmaceuticals-us, KOWA CO., LTD., Regeneron Pharmaceuticals, Inc., and Bausch Health Companies, Inc.
Scope of the Study
Market Segments Covered in the Report:
By Type
- Proliferative
- Diabetic Macular Edema (DME)
By Treatment Type
- Anti VEGF Drug
- Steroid Implants
- Laser Surgeries
- Vitrectomy
By Country
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
Key Market Players
List of Companies Profiled in the Report:
- Allergan PLC (Abbvie, Inc.)
- Bayer AG
- Alimera Sciences, Inc.
- Novartis AG
- Pfizer, Inc.
- F-Hoffmann-La Roche Ltd.
- Ampio Pharmaceuticals-us
- KOWA CO., LTD.
- Regeneron Pharmaceuticals, Inc.
- Bausch Health Companies, Inc.
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Asia Pacific Diabetic Retinopathy Market, by Type
1.4.2 Asia Pacific Diabetic Retinopathy Market, by Treatment Type
1.4.3 Asia Pacific Diabetic Retinopathy Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Strategies Deployed in Diabetic Retinopathy Market
Chapter 4. Asia Pacific Diabetic Retinopathy Market by Type
4.1 Asia Pacific Proliferative Market by Country
4.2 Asia Pacific Diabetic Macular Edema (DME) Market by Country
Chapter 5. Asia Pacific Diabetic Retinopathy Market by Treatment Type
5.1 Asia Pacific Anti VEGF Drug Market by Country
5.2 Asia Pacific Steroid Implants Market by Country
5.3 Asia Pacific Laser Surgeries Market by Country
5.4 Asia Pacific Vitrectomy Market by Country
Chapter 6. Asia Pacific Diabetic Retinopathy Market by Country
6.1 China Diabetic Retinopathy Market
6.1.1 China Diabetic Retinopathy Market by Type
6.1.2 China Diabetic Retinopathy Market by Treatment Type
6.2 Japan Diabetic Retinopathy Market
6.2.1 Japan Diabetic Retinopathy Market by Type
6.2.2 Japan Diabetic Retinopathy Market by Treatment Type
6.3 India Diabetic Retinopathy Market
6.3.1 India Diabetic Retinopathy Market by Type
6.3.2 India Diabetic Retinopathy Market by Treatment Type
6.4 South Korea Diabetic Retinopathy Market
6.4.1 South Korea Diabetic Retinopathy Market by Type
6.4.2 South Korea Diabetic Retinopathy Market by Treatment Type
6.5 Singapore Diabetic Retinopathy Market
6.5.1 Singapore Diabetic Retinopathy Market by Type
6.5.2 Singapore Diabetic Retinopathy Market by Treatment Type
6.6 Malaysia Diabetic Retinopathy Market
6.6.1 Malaysia Diabetic Retinopathy Market by Type
6.6.2 Malaysia Diabetic Retinopathy Market by Treatment Type
6.7 Rest of Asia Pacific Diabetic Retinopathy Market
6.7.1 Rest of Asia Pacific Diabetic Retinopathy Market by Type
6.7.2 Rest of Asia Pacific Diabetic Retinopathy Market by Treatment Type
Chapter 7. Company Profiles
7.1 Alimera Sciences, Inc.
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Regional Analysis
7.1.4 Research & Development Expense
7.1.5 Recent strategies and developments:
7.1.5.1 Partnerships, Collaborations, and Agreements:
7.1.5.2 Geographical Expansions:
7.2 F. Hoffmann-La Roche Ltd.
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Segmental and Regional Analysis
7.2.4 Research & Development Expense
7.2.5 Recent strategies and developments:
7.2.5.1 Partnerships, Collaborations, and Agreements:
7.2.5.2 Approvals and Trials:
7.3 Bausch Health Companies, Inc.
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Segmental and Regional Analysis
7.3.4 Research & Development Expense
7.3.5 Recent strategies and developments:
7.3.5.1 Partnerships, Collaborations, and Agreements:
7.3.5.2 Approvals and Trials:
7.4 Bayer AG
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Segmental and Regional Analysis
7.4.4 Research & Development Expense
7.4.5 Recent strategies and developments:
7.4.5.1 Approvals and Trials:
7.5 Pfizer, Inc.
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Regional & Segmental Analysis
7.5.4 Research & Development Expense
7.6 Novartis AG
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Segmental and Regional Analysis
7.6.4 Research & Development Expense
7.7 Allergan PLC (AbbVie, Inc.)
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Regional Analysis
7.7.4 Research & Development Expense
7.7.5 Recent strategies and developments:
7.7.5.1 Partnerships, Collaborations, and Agreements:
7.8 Regeneron Pharmaceuticals, Inc.
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Research & Development Expense
7.8.3.1 Approvals and Trials:
7.9 Ampio Pharmaceuticals, Inc.
7.9.1 Company Overview
7.10. Kowa Company, Ltd.
7.10.1 Company Overview
TABLE 1 Asia Pacific Diabetic Retinopathy Market, 2017 - 2020, USD Million
TABLE 2 Asia Pacific Diabetic Retinopathy Market, 2021 - 2027, USD Million
TABLE 3 Asia Pacific Diabetic Retinopathy Market by Type, 2017 - 2020, USD Million
TABLE 4 Asia Pacific Diabetic Retinopathy Market by Type, 2021 - 2027, USD Million
TABLE 5 Asia Pacific Proliferative Market by Country, 2017 - 2020, USD Million
TABLE 6 Asia Pacific Proliferative Market by Country, 2021 - 2027, USD Million
TABLE 7 Asia Pacific Diabetic Macular Edema (DME) Market by Country, 2017 - 2020, USD Million
TABLE 8 Asia Pacific Diabetic Macular Edema (DME) Market by Country, 2021 - 2027, USD Million
TABLE 9 Asia Pacific Diabetic Retinopathy Market by Treatment Type, 2017 - 2020, USD Million
TABLE 10 Asia Pacific Diabetic Retinopathy Market by Treatment Type, 2021 - 2027, USD Million
TABLE 11 Asia Pacific Anti VEGF Drug Market by Country, 2017 - 2020, USD Million
TABLE 12 Asia Pacific Anti VEGF Drug Market by Country, 2021 - 2027, USD Million
TABLE 13 Asia Pacific Steroid Implants Market by Country, 2017 - 2020, USD Million
TABLE 14 Asia Pacific Steroid Implants Market by Country, 2021 - 2027, USD Million
TABLE 15 Asia Pacific Laser Surgeries Market by Country, 2017 - 2020, USD Million
TABLE 16 Asia Pacific Laser Surgeries Market by Country, 2021 - 2027, USD Million
TABLE 17 Asia Pacific Vitrectomy Market by Country, 2017 - 2020, USD Million
TABLE 18 Asia Pacific Vitrectomy Market by Country, 2021 - 2027, USD Million
TABLE 19 Asia Pacific Diabetic Retinopathy Market by Country, 2017 - 2020, USD Million
TABLE 20 Asia Pacific Diabetic Retinopathy Market by Country, 2021 - 2027, USD Million
TABLE 21 China Diabetic Retinopathy Market, 2017 - 2020, USD Million
TABLE 22 China Diabetic Retinopathy Market, 2021 - 2027, USD Million
TABLE 23 China Diabetic Retinopathy Market by Type, 2017 - 2020, USD Million
TABLE 24 China Diabetic Retinopathy Market by Type, 2021 - 2027, USD Million
TABLE 25 China Diabetic Retinopathy Market by Treatment Type, 2017 - 2020, USD Million
TABLE 26 China Diabetic Retinopathy Market by Treatment Type, 2021 - 2027, USD Million
TABLE 27 Japan Diabetic Retinopathy Market, 2017 - 2020, USD Million
TABLE 28 Japan Diabetic Retinopathy Market, 2021 - 2027, USD Million
TABLE 29 Japan Diabetic Retinopathy Market by Type, 2017 - 2020, USD Million
TABLE 30 Japan Diabetic Retinopathy Market by Type, 2021 - 2027, USD Million
TABLE 31 Japan Diabetic Retinopathy Market by Treatment Type, 2017 - 2020, USD Million
TABLE 32 Japan Diabetic Retinopathy Market by Treatment Type, 2021 - 2027, USD Million
TABLE 33 India Diabetic Retinopathy Market, 2017 - 2020, USD Million
TABLE 34 India Diabetic Retinopathy Market, 2021 - 2027, USD Million
TABLE 35 India Diabetic Retinopathy Market by Type, 2017 - 2020, USD Million
TABLE 36 India Diabetic Retinopathy Market by Type, 2021 - 2027, USD Million
TABLE 37 India Diabetic Retinopathy Market by Treatment Type, 2017 - 2020, USD Million
TABLE 38 India Diabetic Retinopathy Market by Treatment Type, 2021 - 2027, USD Million
TABLE 39 South Korea Diabetic Retinopathy Market, 2017 - 2020, USD Million
TABLE 40 South Korea Diabetic Retinopathy Market, 2021 - 2027, USD Million
TABLE 41 South Korea Diabetic Retinopathy Market by Type, 2017 - 2020, USD Million
TABLE 42 South Korea Diabetic Retinopathy Market by Type, 2021 - 2027, USD Million
TABLE 43 South Korea Diabetic Retinopathy Market by Treatment Type, 2017 - 2020, USD Million
TABLE 44 South Korea Diabetic Retinopathy Market by Treatment Type, 2021 - 2027, USD Million
TABLE 45 Singapore Diabetic Retinopathy Market, 2017 - 2020, USD Million
TABLE 46 Singapore Diabetic Retinopathy Market, 2021 - 2027, USD Million
TABLE 47 Singapore Diabetic Retinopathy Market by Type, 2017 - 2020, USD Million
TABLE 48 Singapore Diabetic Retinopathy Market by Type, 2021 - 2027, USD Million
TABLE 49 Singapore Diabetic Retinopathy Market by Treatment Type, 2017 - 2020, USD Million
TABLE 50 Singapore Diabetic Retinopathy Market by Treatment Type, 2021 - 2027, USD Million
TABLE 51 Malaysia Diabetic Retinopathy Market, 2017 - 2020, USD Million
TABLE 52 Malaysia Diabetic Retinopathy Market, 2021 - 2027, USD Million
TABLE 53 Malaysia Diabetic Retinopathy Market by Type, 2017 - 2020, USD Million
TABLE 54 Malaysia Diabetic Retinopathy Market by Type, 2021 - 2027, USD Million
TABLE 55 Malaysia Diabetic Retinopathy Market by Treatment Type, 2017 - 2020, USD Million
TABLE 56 Malaysia Diabetic Retinopathy Market by Treatment Type, 2021 - 2027, USD Million
TABLE 57 Rest of Asia Pacific Diabetic Retinopathy Market, 2017 - 2020, USD Million
TABLE 58 Rest of Asia Pacific Diabetic Retinopathy Market, 2021 - 2027, USD Million
TABLE 59 Rest of Asia Pacific Diabetic Retinopathy Market by Type, 2017 - 2020, USD Million
TABLE 60 Rest of Asia Pacific Diabetic Retinopathy Market by Type, 2021 - 2027, USD Million
TABLE 61 Rest of Asia Pacific Diabetic Retinopathy Market by Treatment Type, 2017 - 2020, USD Million
TABLE 62 Rest of Asia Pacific Diabetic Retinopathy Market by Treatment Type, 2021 - 2027, USD Million
TABLE 63 Key Information – Alimera Sciences, Inc.
TABLE 64 KEY INFORMATION – F. HOFFMANN-LA ROCHE LTD.
TABLE 65 key information – Bausch Health Companies, Inc.
TABLE 66 Key Information – Bayer AG
TABLE 67 Key Information – Pfizer, Inc.
TABLE 68 Key Information – Novartis AG
TABLE 69 Key Information – Allergan PLC
TABLE 70 Key Information – Regeneron Pharmaceuticals, Inc.
TABLE 71 Key Information – Ampio Pharmaceuticals, Inc.
TABLE 72 Key Information – Kowa Company, Ltd.
List of Figures
FIG 1 Methodology for the research
FIG 2 Recent strategies and developments: Alimera Sciences, Inc.